-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F8Ur2UUkr/pSIIEYzo+/L4dxBHP8ipBgh6nmVF/VA0WwgYCGzXU1zngMNq7ZcG16 OZ18mcN1eo1xbxK62dgMuQ== 0000950123-98-002067.txt : 19980302 0000950123-98-002067.hdr.sgml : 19980302 ACCESSION NUMBER: 0000950123-98-002067 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980227 SROS: NYSE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LIFECORE BIOMEDICAL INC CENTRAL INDEX KEY: 0000028626 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 410948334 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-35300 FILM NUMBER: 98551315 BUSINESS ADDRESS: STREET 1: 3515 LYMAN BLVD CITY: CHASKA STATE: MN ZIP: 55318-3051 BUSINESS PHONE: 6123684300 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC INC DATE OF NAME CHANGE: 19861214 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN MEDICAL RESEARCH INC DATE OF NAME CHANGE: 19691118 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 9085240400 SC 13D/A 1 AMENDMENT NO. 2 TO SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LIFECORE BIOMEDICAL, INC. ------------------------- (Name of Issuer) COMMON STOCK ------------ (Title of Class of Securities) 532187101 --------- (CUSIP Number) Eric B. Jung, Esq. Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933 (732) 524-1249 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 17, 1998 ----------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box. |_| Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 10 Pages 2 SCHEDULE 13D - --------------------------------- ------------------------------- CUSIP No. 532187101 Page 2 of 10 Pages - --------------------------------- ------------------------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson 22-1024240 - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |_| - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY -0- OWNED BY EACH REPORTING PERSON WITH --------------------------------------------------------------- 8 SHARED VOTING POWER 752,525 --------------------------------------------------------------- 9 SOLE DISPOSITIVE POWER -0- --------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 752,525 - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 752,525 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.1% ---- - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 3 SCHEDULE 13D - --------------------------------- ------------------------------- CUSIP No. 532187101 Page 3 of 10 Pages - --------------------------------- ------------------------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Johnson & Johnson Development Corporation 22-2007137 - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |_| - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey - ------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY -0- OWNED BY EACH REPORTING PERSON WITH --------------------------------------------------------------- 8 SHARED VOTING POWER 752,525 --------------------------------------------------------------- 9 SOLE DISPOSITIVE POWER -0- --------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 752,525 - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 752,525 - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.1% ---- - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 4 CUSIP 532187101 Page 4 of 10 Pages Items 1-7 of the Statement on Schedule 13D filed pursuant to Rule 13d-1 (the "Schedule 13D") of the Rules and Regulations under the Securities Exchange Act of 1934, as amended, by Johnson & Johnson, a New Jersey corporation, and Johnson & Johnson Development Corporation, a New Jersey corporation, relating to the shares of Common Stock, $.01 par value per share (the "Common Stock") of Lifecore Biomedical, Inc. (the "Company"), are hereby amended and restated as follows: Item 1. Security and Issuer: Common Stock, par value $.01 par value Lifecore Biomedical, Inc. 3515 Lyman Boulevard Chaska, Minnesota 55318 Item 2. Identity and Background: (a) Johnson & Johnson ("J&J") and Johnson & Johnson Development Corporation ("JJDC"), both New Jersey corporations. (b) One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933. (c) The principal business of J&J is health care products. JJDC is a wholly-owned subsidiary of J&J engaged in the venture capital business. The name, citizenship, residence or business address and principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) of each director and executive officer of J&J and JJDC is set forth on Appendix A hereto. (d),(e) To the best of J&J's knowledge, neither J&J nor any of its directors or executive officers has, during the past five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. To the best of JJDC's knowledge, neither JJDC nor any of its directors or executive officers has, during the past five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or 5 CUSIP 532187101 Page 5 of 10 Pages mandating activities subject to, Federal or State securities laws of finding any violation with respect to such laws. (f) Not applicable. Item 3. Source and Amount of Funds or Other Consideration: On August 8, 1994, JJDC purchased from the Company 757,396 shares of Common Stock of the Company for an aggregate consideration of $4,000,000, of which $2,600,000 was paid in cash at the closing of the purchase and of which $1,400,000 was paid in cash previously deposited with the Company by Ethicon, Inc. ("Ethicon"), a wholly-owned subsidiary of J&J. Simultaneous with the closing of such purchase, Ethicon assigned to JJDC all of its right, title and interest to any of such Common Stock. On October 18, 1995, JJDC purchased from the Company 205,128 shares of Common Stock of the Company for $2,000,000. No funds were borrowed to finance either purchase described above. On November 15, 1996, JJDC sold 25,000 shares of Common Stock. On November 20, 1996, JJDC sold 15,000 shares of Common Stock. On August 15, 1997, JJDC sold 70,000 shares of Common Stock. On February 12, 1998, JJDC sold 5,000 shares of Common Stock. On February 17, 1998, JJDC sold 95,000 shares of Common Stock. Item 4. Purpose of Transaction: The shares of Common Stock were acquired from the Company for investment purposes. J&J and JJDC have no present plans or proposals which relate to, or would result in, any of the actions enumerated in paragraphs (a) through (j) of this Item. Item 5. Interest in Securities of the Issuer: (a) As of February 26, 1998, J&J and JJDC each had beneficial ownership of an aggregate of 752,525 shares of Common Stock. Based upon the shares of Common Stock outstanding, as reported in the Company's Report on Form 10-Q for the quarter ended December 31, 1997, 752,525 constitute approximately 6.1% of the outstanding shares of the Company's Common Stock. 6 CUSIP 532187101 Page 6 of 10 Pages (b) J&J and JJDC each have shared power to vote and shared power to dispose of all shares described in paragraph (a) above. (c) Except as described in the response to Item 3 hereof, there were no transactions in the Common Stock of the Company effected by J&J or JJDC during the past sixty days. To the best knowledge of J&J and JJDC, no director or executive officer of J&J or JJDC beneficially owns any shares of Common Stock or other securities of the Company. Neither J&J nor JJDC is aware of any transaction in such securities during the past sixty (60) days by any of its executive officers or directors. (d) Not applicable. (e) Not applicable. Item 6. Contracts, Arrangements, etc.: Not applicable. Item 7. Exhibits: Not applicable. 7 CUSIP 532187101 Page 7 of 10 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JOHNSON & JOHNSON Dated: February 26, 1998 By /s/ P. S. Galloway --------------------------- Name: Peter S. Galloway Title: Secretary JOHNSON & JOHNSON DEVELOPMENT CORPORATION Dated: February 26, 1998 By /s/ P.S. Galloway --------------------------- Name: Peter S. Galloway Title: Secretary 8 CUSIP 532187101 Page 8 of 10 Pages SCHEDULE A Board of Directors and Executive Officers of Johnson & Johnson The directors and executive officers of Johnson & Johnson are identified in the table below. Directors of Johnson & Johnson are indicated by an asterisk.
Name Business Address Citizenship Principal Occupation - ---- ---------------- ----------- -------------------- 1. Dr. Gerard N. Burrow (*) Yale New Haven School United States Dean of the Yale University School of 333 Cedar Street Medicine since 1992 New Haven, CT 06510 2. Joan Ganz Cooney (*) Children's Television Workshop United States Chairman, Children's Television Workshop One Lincoln Plaza New York, NY 10023 3. James Cullen (*) Bell Atlantic Corporation United States Vice Chairman of the Board, Bell Atlantic 1310 North Court House Road Corporation Arlington, VA 22201 Johnson & Johnson 4. Robert J. Darretta One Johnson & Johnson Plaza United States Vice President, Finance and Member, New Brunswick, NJ 08933 Executive Committee of Johnson & Johnson 5. Russell C. Deyo Johnson & Johnson United States Vice President, Administration, and One Johnson & Johnson Plaza Member, Executive Committee of Johnson New Brunswick, NJ 08933 & Johnson 6. Roger S. Fine Johnson & Johnson United States Vice President and General Counsel and One Johnson & Johnson Plaza Member, Executive Committee of Johnson New Brunswick, NJ 08933 & Johnson 7. Ronald G. Gelbman Johnson & Johnson United States Member, Executive Committee of Johnson One Johnson & Johnson Plaza & Johnson New Brunswick, NJ 08933 8. Philip M. Hawley (*) Philip M. Hawley United States Former Chairman and Chief Executive Suite 2280 Officer of Carter Hawley Hale Stores, Inc. 444 South Flower Street Los Angeles, CA 90071-2900 9. JoAnn H. Heisen Johnson & Johnson United States Corporate Vice President, Chief One Johnson & Johnson Plaza Information Officer, and Member, New Brunswick, NJ 08933 Executive Committee of Johnson & Johnson 10. Ann Dibble Jordan (*) Johnson & Johnson United States Director of various other corporations One Johnson & Johnson Plaza New Brunswick, NJ 08933 11. Christian A. Koffmann Johnson & Johnson France Member, Executive Committee of Johnson One Johnson & Johnson Plaza & Johnson New Brunswick, NJ 08933
9 CUSIP 532187101 Page 9 of 10 Pages
Name Business Address Citizenship Principal Occupation - ---- ---------------- ----------- -------------------- 12. Arnold G. Langbo (*) 111 Capital Avenue, S.W. Canada Chairman of the Board and Chief Executive Battle Creek, MI 49015 Officer of the Kellogg Company 13. Ralph S. Larsen (*) Johnson & Johnson United States Chairman, Board of Directors, Chief One Johnson & Johnson Plaza Executive Officer and Chairman, Executive New Brunswick, NJ 08933 Committee, of Johnson & Johnson 14. James T. Lenehan Johnson & Johnson United States Member, Executive Committee of Johnson One Johnson & Johnson Plaza & Johnson New Brunswick, NJ 08933 15. Dr. John S. Mayo (*) AT&T Bell Laboratories, Inc. United States President, Emeritus, AT&T Bell 600 Mountain Avenue Laboratories, Inc. Murray Hill, NJ 07974 16. Thomas S. Murphy (*) Capital Cities/ABC, Inc. United States Former Chairman of the Board and Chief 77 West 66th Street Executive Officer of Capital Cities/ABC New York, NY 10023-6298 17. Paul J. Rizzo (*) IBM Corporation United States Retired Vice Chairman of International Old Orchard Road Business Machines Corporation Armonk, NY 10504 18. Henry B. Schact (*) Lucent Technologies United States Chairman of the Board of Lucent 600 Mountain Avenue Technologies Murray Hill, N.J. 07974 19. Maxine F. Singer, Ph.D.(*) Carnegie Institution of Washington United States President of the Carnegie Institution of 1530 P Street, N.W. Washington Washington, D.C. 20005-1910 20. Roger B. Smith (*) Johnson & Johnson United States Retired Chairman of General Motors One Johnson & Johnson Plaza Corporation, Member of the Business New Brunswick NJ 08933 Council and Trustee of the Alfred P. Sloan Foundation 21. Robert N. Wilson (*) Johnson & Johnson United States Vice Chairman, Board of Directors and One Johnson & Johnson Plaza Vice Chairman, Executive Committee of New Brunswick, NJ 08933 Johnson & Johnson
10 CUSIP 532187101 Page 10 of 10 Pages Board of Directors and Executive Officers of Johnson & Johnson Development Corporation The directors and executive officers of Johnson & Johnson Development Corporation are identified in the table below. Directors of Johnson & Johnson Development Corporation are indicated by an asterisk.
Name Business Address Citizenship Principal Occupation 1. Blair M. Flicker Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development Corporation New Brunswick, NJ 08933 2. Peter S. Galloway (*) Johnson & Johnson United States Secretary and Associate General Counsel of One Johnson & Johnson Plaza Johnson & Johnson; and Vice President and New Brunswick, NJ 08933 Secretary of Johnson & Johnson Development Corporation 3. Thomas M. Gorrie, Ph.D. Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development New Brunswick, NJ 08933 Corporation 4. Susan Lambert Johnson & Johnson United Vice President of One Johnson & Johnson Plaza Kingdom Johnson & Johnson Development New Brunswick, NJ 08933 5. Alfred T. Mays Johnson & Johnson United States President, McNeil Specialty Products Company; One Johnson & Johnson Plaza and Vice President of Johnson & Johnson New Brunswick, NJ 08933 Development Corporation 6. Ting Pau Oei (*) Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development Corporation New Brunswick, NJ 08933 7. James R. Utaski (*) Johnson & Johnson United States Corporate Vice President, Business Development One Johnson & Johnson Plaza of Johnson & Johnson; President of Johnson New Brunswick, NJ 08933 & Johnson Development Corporation 8. Dr. Brad Vale Johnson & Johnson United States Vice President of One Johnson & Johnson Plaza Johnson & Johnson Development Corporation New Brunswick, NJ 08933
-----END PRIVACY-ENHANCED MESSAGE-----